-
Comment on: A Multiomic Analysis to Identify Drivers of Subclinical Vascular Disease in Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Biao Song, Pan Shen
Click on the article title to read more.
-
Reply Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Sigrid V. Hestetun, Kristine L. Haftorn, Ketil Størdal, Helga Sanner
Click on the article title to read more.
-
Association of thigh intramuscular fat infiltration with incident knee and hip osteoarthritis: a longitudinal cohort study: Comment on the article Weng Q et al Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Duygu Tecer, Sedat Yilmaz
Click on the article title to read more.
-
Comments on “Peripheral Biomarker Signatures in Rheumatoid Arthritis‐Associated Interstitial Lung Disease” Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Bi‐yun Yao, Ya‐zhen Su, Yang Liu, Li‐Yun Zhang
Click on the article title to read more.
-
Antiphospholipid syndrome: an antibody‐mediated disease with emerging therapeutic opportunities Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Thalia G. Newman, Jason S. Knight
Antiphospholipid syndrome (APS) is an autoimmune thrombo‐inflammatory disorder characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS manifestations, including microvascular injury and diffuse
-
Precision Medicine in Pediatric Autoimmunity: Leniolisib Treatment of Childhood‐Onset Lupus Nephritis Due to Activated PI3K‐Delta Syndrome (APDS) Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Jonathan P. Lim, Mansooreh Ahmadian, Hongyu Du, Christian Rickert, Tusharkanti Ghosh, Fuyong Xing, Angela Minic, Sara A. Johnson, Jason P. Weinman, Nicholas Willard, Clara Lin, Jennifer C. Cooper, Melisha Hanna, Vijaya Knight, Debashis Ghosh, Kimberly R. Jordan, Elena WY Hsieh
-
A Historical Perspective on Approaches to Understanding the Genetics of Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 S. Louis Bridges, Betty P. Tsao, Peter K. Gregersen
Click on the article title to read more.
-
Trio whole exome sequencing in Chinese childhood‐onset lupus reveals novel candidate genes Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Jianyang Ma, Yuting Qin, Soon‐Min Hong, Thuvaraka Ware, Guojun Hou, Jingjing Tan, Chengmei Xie, Pingjing Zhang, Xiaoqian Wu, Todor Arsov, Lanfang Cao, T Daniel Andrews, Philip Wu, Qian Shen, Huihua Ding, Nan Shen, Carola G. Vinuesa, Yuke He
ObjectivesSystemic lupus erythematosus (SLE) is an autoimmune disease in which rare and common gene variants contribute to pathogenesis. Severe sporadic disease in children is often explained by ‘de novo’ variants that can be uncovered by trio sequencing.MethodsWhole exome sequencing was performed in 50 Chinese trios with childhood‐onset SLE (cSLE). Rare coding variants in SLE‐associated genes and
-
HLA class I‐downregulated senescent epidermal basal cells orchestrate skin pathology in cutaneous lupus erythematosus Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Sena Yamamoto, Yuki Saito, Tsukasa Sato, Seina Nakano, Dain Kasseki, Ayaka Nagao, Norihiro Miura, Kentaro Nagaoka, Arisa Kita, Maki Miyajima, Shogo Ijima, Koji Taniguchi, Atsushi Niida, Takako S. Chikenji
ObjectiveTo investigate the role of senescent epidermal basal cells in cutaneous lupus erythematosus (CLE) pathogenesis using skin samples from patients with CLE and a mouse model of systemic lupus erythematosus (SLE).MethodsCellular senescence profiling utilized datasets from the NCBI Gene Expression Omnibus database and Accelerating Medicines Partnership® (AMP®) Phase 1‐Metro. Gene array data from
-
Hand swelling and other non‐Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohorts Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Iqtidar Hanif, Shervin Assassi, Maureen D. Mayes, Zsuzsanna H. McMahan, Meng Zhang, Julio Charles, John M. VanBuren, Jessica S. Alvey, Kimia Ghaffari, Elana J. Bernstein, Flavia V. Castelino, Lorinda Chung, Luke Evnin, Tracy M. Frech, Jessica K. Gordon, Faye N. Hant, Laura K. Hummers, Dinesh Khanna, Kimberly S. Lakin, Dorota Lebiedz‐Odrobina, Yiming Luo, Ashima Makol, Jerry A. Molitor, Duncan F. Moore
ObjectiveRaynaud's phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts.MethodsAll patient data in the GENISOS and
-
Global burden of osteoarthritis attributable to high body mass index, 1990‐2021: insights from the Global Burden of Disease study 2021 Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Yi Lu, Wenyu Xiao, Kun Tao
ObjectiveThis study quantifies the global burden of osteoarthritis (OA) attributable to high body mass index (BMI) from 1990 to 2021 using the Global Burden of Disease (GBD) 2021 data.MethodsUtilizing GBD 2021 data, this research examines the OA burden related to high BMI across 204 countries and regions. Statistical analyses were performed to profile disease burdens, and joinpoint regression was used
-
The incidence of juvenile idiopathic arthritis in Norway varies with the latitude gradient: Are we rigorous enough? Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Sheng Qiu, James Cheng‐Chung Wei, Zhenhua Ying
Click on the article title to read more.
-
A National Academies’ Committee Reviews Women's Health Research at the NIH and Makes Recommendations Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-19 Jane E. Salmon, Nancy E. Lane
Click on the article title to read more.
-
Complex regulatory interactions at GDF5 shape joint morphology and osteoarthritis disease risk Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Clarissa R. Coveney, David Maridas, Hao Chen, Pushpanathan Muthuirulan, Zun Liu, Evelyn Jagoda, Siddharth Yarlagadda, Mohammadreza Movahhedi, Benedikt Proffen, Babak Dashtdar, Mahdi Aghaalikhani, Daniel Richard, Vicki Rosen, Ata M. Kiapour, Terence D. Capellini
ObjectivesTo reveal causal level osteoarthritis (OA) disease biology by targeting regulatory interactions at GDF5.MethodsBy investigating different GDF5 regulatory regions (R2, R3‐5, R7‐R9, R18‐20, GROW1) we explored their functional impacts on gene expression and joint morphology in vivo and in vitro. We additionally modeled OA variants in said enhancers in vitro and in vivo mouse models for expression
-
Genetics of Childhood‐onset Systemic Lupus Erythematosus (cSLE) Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Raffaella Carlomagno, Nicholas Gold, Fangming Liao, Jingjing Cao, Paul D. Arnold, Christie L. Burton, Jennifer Crosbie, Daniela Dominguez, Dafna D. Gladman, Mariko Ishimori, Caroline Jefferies, Diane L. Kamen, Sylvia Kamphuis, Marisa S. Klein‐Gitelman, Andrea M. Knight, Chia‐Chi J. Lee, Deborah M. Levy, Karen B. Onel, Andrew D. Paterson, Christine A. Peschken, Janet E. Pope, Russell J. Schachar, Earl
ObjectivesGenome wide association studies (GWAS) have identified >100 loci for systemic lupus erythematosus (SLE). These loci may also impact age of diagnosis. We aimed to identify genetic variants for age of SLE diagnosis, and to complete a GWAS of childhood‐onset SLE (cSLE) diagnosed <18 years of age.MethodsPatients met ACR and/or SLICC SLE classification criteria, had documented age at diagnosis
-
Achilles tendon involvement of juvenile xanthogranuloma Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Zhe Guo, Yi Yuan, Wenjing Li, Lan Li
Click on the article title to read more.
-
Reply to letter to the editor Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Rongliang Wang, Wayne Yuk Wai Lee
Click on the article title to read more.
-
Differences in dynamics of specific anti‐nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Hugo J. van Dooren, Mieke van Schaik, Annemarie L. Dorjée, Eline J. Arends, Meggan Mackay, Cooney Laura, David A. Fox, David Wofsy, Dawn Smilek, Cynthia Aranow, Maria Dall'Era, Tom W.J. Huizinga, Cees van Kooten, René E.M. Toes, Betty Diamond, Y.K. Onno Teng, Jolien Suurmond
ObjectiveThe presence of anti‐nuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti‐dsDNA is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated with disease activity. Antibody dynamics of other
-
The Dynamics of ANA Production in SLE: New Insights for New Therapies Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Martin Aringer, David S. Pisetsky
Click on the article title to read more.
-
Dietary polyunsaturated fatty acid and the risk of rheumatoid arthritis: Insights from genetic predisposition and proteomics Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Li Chen, Tianqi Tan, Yashu Chen, Feipeng Cui, Huimin Chen, Ying Zhao, Yuhan Tang, Xia Xiang, Qianchun Deng
-
Innate Lymphoid Cell phenotypic and functional alterations in systemic Juvenile Idiopathic Arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Linda Quatrini, Cecilia Ciancaglini, Ivan Caiello, Silvia Santopolo, Manuela Pardeo, Valentina Matteo, Elena Loricchio, Donato Amodio, Elena Morrocchi, Giulio Olivieri, Paolo Palma, Antonella Insalaco, Marco Francesco Natale, Arianna de Matteis, Nicola Tumino, Claudia Bracaglia, Paola Vacca, Lorenzo Moretta, Fabrizio De Benedetti, Giusi Prencipe
ObjectivesSystemic juvenile idiopathic arthritis (sJIA) is a chronic childhood disease classically attributed to innate immune cell dysregulation. This study aimed to elucidate the role of innate lymphoid cells (ILCs), including natural killer (NK) cells and helper‐ILCs (hILCs), in sJIA during clinically inactive disease (CID) through phenotypic and functional analysis.MethodsPeripheral ILCs from children
-
A Classic Case of Linear IgA Bullous Dermatosis in a Child Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-13 Eduardo López‐Vera, Jose A Llamas‐Carmona, Juan S Rodríguez‐Moncada
Click on the article title to read more.
-
Three-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Sarah Ringold, Mei-Sing Ong, George Tomlinson, Marc D. Natter, Laura E. Schanberg, Vincent Del Gaizo, Brian M. Feldman, Katherine L. Murphy, Yukiko Kimura
To assess the impact of differences in the timing of initial biologic DMARD (bDMARD) therapy using the CARRA STOP-JIA polyarticular JIA (pJIA) consensus treatment plans (CTPs) study on outcomes through 3 years.
-
EULAR/American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Yongdong Zhao, Melissa S. Oliver, Anja Schnabel, Eveline Y. Wu, Zhaoyi Wang, Achille Marino, Cassyanne L. Aguiar, Jonathan D. Akikusa, Ummusen Kaya Akca, Beverley Almeida, Simone Appenzeller, Erin Balay‐Dustrude, Ozge Basaran, Matthew L. Basiaga, Yelda Bilginer, David A. Cabral, Martina Capponi, Nathan Donaldson, Bugra Han Egeli, Emily J. Fox, Antonella Insalaco, Ramesh S. Iyer, Annette F. Jansson
ObjectiveTo develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR).MethodsThis international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3)
-
EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Hanna W. van Steenbergen, Frank Doornkamp, Stefano Alivernini, John Backlund, Catalin Codreanu, Stanley B. Cohen, Bernard Combe, Andrew P. Cope, Kevin D. Deane, Bryant R. England, Marie Falahee, Pascal H. P. de Jong, Arnd Kleyer, Diane Lacaille, Bertha Maat, Kulveer Mankia, Elise van Mulligen, György Nagy, Liam J. O'Neil, Linda Rodamaker, Ilfita Sahbudin, Dirkjan van Schaardenburg, Alexandre Sepriano
ObjectiveThe field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but a validated risk stratification method is lacking. This work was undertaken to develop a risk stratification method for persons presenting with arthralgia considered to be at risk of RA.MethodsA joint EULAR/American College of Rheumatology (ACR) expert committee was established
-
Limitations of Machine Learning‐Based Feature Importance in Osteoarthritis Biomarker Discovery Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Yoshiyasu Takefuji
Click on the article title to read more.
-
Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid‐dependent polymyalgia rheumatica Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Baptiste Chevet, Aghiles Souki, Emmanuel Nowak, Guillermo Carvajal‐Alegria, Emmanuelle Dernis, Christophe Richez, Marie‐Elise Truchetet, Daniel Wendling, Eric Toussirot, Aleth Perdriger, Jacques‐Eric Gottenberg, Renaud Felten, Bruno Fautrel, Anne Lohse, Laurent Chiche, Pascal Hilliquin, Catherine Le Henaff, Benjamin Dervieux, Guillaume Direz, Isabelle Chary‐Valckenaere, Divi Cornec, Dewi Guellec, Thierry
ObjectiveThe SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks.This study aimed to assess relapse rates after stopping TCZ in patients achieving remission at week 24.MethodsIn the randomized study, 101 patients received intravenous TCZ (8 mg/kg) or placebo for 24 weeks
-
Tapering in Rheumatoid Arthritis: A Path to Predict Flares Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Elise van Mulligen, Jon T Giles, Angelique EAM Weel
Click on the article title to read more.
-
Reply to: Circulating interferon alpha protein measured with digital ELISA as a biomarker for modified Rodnan skin score progression in limited systemic sclerosis: comment on the article from Di Donato et al Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Stefano Di Donato, Christopher P. Denton, Francesco Del Galdo
Click on the article title to read more.
-
Challenges and Future Directions in Machine Learning for Osteoarthritis Prediction ‐ Reply to the comments by Professor Takefuji Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-08 Zijian Kang, Sheng‐Ming Dai
Click on the article title to read more.
-
Circulating interferon alpha protein measured with digital ELISA as a biomarker for modified Rodnan skin score progression in limited systemic sclerosis: comment on the article from Di Donato et al Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-07 Carine Schmidt, François Maillet, Vincent Bondet, Darragh Duffy, Luc Mouthon, Benjamin Chaigne, Mathieu P Rodero
‐
-
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-07 Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'Era, Alí Duarte‐García, Linda T. Hiraki, Brad H. Rovin, Mary Beth F. Son, Anthony Alvarado, Cynthia Aranow, April Barnado, Anna Broder, Hermine I. Brunner, Vaidehi Chowdhary, Gabriel Contreras, Christele Felix, Elizabeth D. Ferucci, Keisha L. Gibson, Aimee O. Hersh, Peter M. Izmirly, Kenneth Kalunian, Diane Kamen, Brandi Rollins, Benjamin
ObjectiveThe objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.MethodsThe Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading
-
Longitudinal Associations Between Baseline Sarcopenia and Knee Osteoarthritis Progression and Risk of Knee Replacement Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-06 Tianxing Wu, Xiaoshuai Wang, Zhuojian Cai, Peihua Cao, Qin Dang, Weijie Zhou, Jiawei Xie, Jie Chen, Taiwei Wang, Gaochenzi Tao, Weiyu Han, Zhaohua Zhu, Jian Wang, David J Hunter, Rocco Barazzoni, Changhai Ding, Jia Li
-
Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and TYK2 Inhibitors via IL10 Antagonism Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-05 Sami Giryes, Chi Wong, Charlie Bridgewood, Mark Harland, Ala Altaie, Nicole McDermott, Kerem Abacar, Abhay Rao, Almas Khan, Tristan McMillan, Peter Loughenbery, Robert Dunsmuir, Vishal Borse, Tom Macleod, Dennis McGonagle
-
Gout and NLRP3 inflammasome biology Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-05 Raewyn Poulsen, Nicola Dalbeth
-
Associations and Diagnostic Accuracy of Ultrasound Features in Knee Osteoarthritis: Cross‐sectional Results from a Large Community‐based Cohort: comment on the article by Yates KA et al. Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-05 Haojie Guan, Haidong Zhou, Hongyu Xu, Hejing Pan
Click on the article title to read more.
-
Effect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-02 Brad H. Rovin, Clarissa Cassol, Samir V. Parikh, Amit Saxena, Neil Solomons, Vanessa Birardi, Ernie Yap, Clint W. Abner, David R.W. Jayne, Robert B. Huizinga
ObjectiveThis study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials.MethodsPatients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose glucocorticoids. Patients had baseline kidney biopsies within
-
Voclosporin nephrotoxicity: a myth debunked? Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-02 Anthony Chang
Click on the article title to read more.
-
Letter to Editor regarding "Plasma Proteomic Profiles Predict Individual Future Osteoarthritis Risk" Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-05-02 Qing Wang, Shuxing Xing
Click on the article title to read more.
-
Correction to “Novel Genetic Loci in Early‐Onset Gout Derived From Whole‐Genome Sequencing of an Adolescent Gout Cohort” Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-29
Ji A, Sui Y, Xuo X, et al. Novel Genetic Loci in Early-Onset Gout Derived From Whole-Genome Sequencing of an Adolescent Gout Cohort. Arthritis Rheumatol. 2025 Jan;77(1):107–115. In the article noted above, the author name Xiapeng Ji is misspelled. The correct spelling is Xiaopeng Ji. We apologize for this error.
-
Aberrant glycosylation of IgG in children with active lupus nephritis alters podocyte metabolism and causes podocyte injury Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-29 Rhea Bhargava, Rohit Upadhyay, Cong Zhao, Prasad Katakam, Scott Wenderfer, Jing Chen, Hua He, Richard Cummings, Maria G. Tsokos, George C. Tsokos
BackgroundPodocytes are integral to the maintenance of the glomerular filtration barrier. Their injury results in proteinuria and disease progression in lupus nephritis (LN). Aberrant IgG glycosylation drives podocyte injury in LN and leads to cytoskeletal rearrangement, motility changes and decreased nephrin production. Based on these findings, we hypothesized that IgG glycosylation patterns differentiate
-
Issue Information Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-29
Click on the article title to read more.
-
In This Issue Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-29
Click on the article title to read more.
-
Journal Club Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-29
Click on the article title to read more.
-
Clinical Connections Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-29
Click on the article title to read more.
-
Comparative Analysis of Circulating and Synovial Immune Cells in Early Untreated Rheumatoid Arthritis and their relationship with molecular pathology and disease outcomes Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-27 Felice Rivellese, Elena Pontarini, Liliane Fossati-Jimack, Rita A. Moura, Vasco C. Romão, João Eurico Fonseca, Alessandra Nerviani, Cankut Çubuk, Katriona Goldmann, Giovanni Giorli, Myles Lewis, Michele Bombardieri, Costantino Pitzalis
To assess the relationship of circulating and synovial immune cells with synovial molecular pathology and disease outcomes in early Rheumatoid Arthritis (RA).
-
Correction to “Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell‐Related Autoimmune Diseases” Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28
Arthritis Rheumatol. 2023 Jul;75(7):1187-1202. doi: 10.1002/art.42462. Epub 2023 Apr 19. In Figure 3A, the labels for the two WT TACI-Fc comparators on the y-axis were inverted. The 2nd bar from the top should have been labeled “WT TACI 30-110 Ig” and the 3rd bar from the top should have been labeled “WT TACI 13-118 Ig.” We apologize for this error.
-
Response to the comments on “Plasma proteomic profiles predict individual future osteoarthritis risk” Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Zijian Kang, Qiang Tong, Sheng‐Ming Dai
Click on the article title to read more.
-
Reply to Guan, et al. Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Katherine A. Yates, Amanda E. Nelson
Click on the article title to read more.
-
3‐year Results of Tapering TNFi to Withdrawal Compared to Stable TNFi Among Patients with Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Kaja E. Kjørholt, Nina Paulshus Sundlisæter, Anna‐Birgitte Aga, Joseph Sexton, Inge C. Olsen, Åse S. Lexberg, Tor M. Madland, Hallvard Fremstad, Christian A. Høili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger M. Hansen, Ellen Moholt, Karen Holten, Till Uhlig, Tore K. Kvien, Daniel H. Solomon, Désirée van der Heijde, Espen A. Haavardsholm, Siri Lillegraven
ObjectivesTapering of tumor necrosis factor inhibitor (TNFi) treatment in rheumatoid arthritis (RA) remission is debated. We assessed the effect of tapering TNFi to withdrawal versus continued stable TNFi on flare‐free survival and joint damage progression over three years.MethodsARCTIC REWIND was a multicenter, open‐label, non‐inferiority trial including patients with RA in remission for ≥12 months
-
Reply Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Tuhina Neogi, Maureen Dubreuil, Christine Peloquin, Lee Marinko, James Camarinos, David T. Felson, Deepak Kumar
Click on the article title to read more.
-
Targeting Long Noncoding RNA H19 in Subchondral Bone Osteocytes and the Alleviation of Cartilage Degradation in Osteoarthritis: Comment on the Article by Wang et al. Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Suqi Wu, Guangyin Yu, Yankui Leng
Click on the article title to read more.
-
Deep immunophenotyping and clustering identifies biomarkers predictive of lymphoma in primary Sjögren disease Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Cindy Marques, Paul Régnier, Anna Maciejewski‐Duval, Clara Richard de Vesvrotte, Thomas Vazquez, Camille Montardi, Bénédicte Manoury, Karim Dorgham, Cloé Comarmond, Arsène Mekinian, Michelle Rosenzwajg, Alexandre Le Joncour, Matheus Vieira, Georgina Maalouf, Gaëlle Leroux, Fanny Domont, Anne‐Claire Desbois, Adrien Mirouse, David Klatzmann, JE Gottenberg, Patrice Cacoub, David Saadoun
ObjectivePatients with primary Sjögren Disease (pSD) are prone to develop non‐Hodgkin's lymphoma (NHL‐pSD) but relevant biomarkers are lacking. We aimed to determine new biomarkers predictive of NHL in patients with pSD.Methods206 pSD patients fulfilling ACR/EULAR 2016 criteria were included and divided into three groups: pSD, lymphoproliferative pSD (Arl‐pSD), and NHL‐pSD. Deep flow cytometry immunophenotyping
-
Beyond the Numbers: Recognizing Disease Severity and Hidden Influences in Physical Therapy for Knee osteoarthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Yadi Li
Click on the article title to read more.
-
Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-28 Michelle L. Robinette, Hetty E. Carraway
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy. Myeloid and lymphoid hematologic malignancy have long been recognized in
-
Secular trends in biologic prescribing for psoriasis and psoriatic arthritis, 2014‐2024 Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-23 Mahum Mirza, Jean W. Liew, Mike Putman, Shikha Singla
Click on the article title to read more.
-
Epitope spreading and systemic sclerosis: comment on the article by Kotani et al Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-23 Ranjeet Singh Mahla
Click on the article title to read more.
-
Subcutaneous Panniculitis‐like T‐cell Lymphoma Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-22 Shae Chambers, Caitlyn N. Myrdal, Victoria P. Werth
Click on the article title to read more.
-
Clinical Images: Subacromial bursitis with rice bodies as an initial solo presentation of rheumatoid arthritis Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-20 Takeshi Zoshima
Click on the article title to read more.
-
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease‐modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK‐pot" study) Arthritis Rheumatol. (IF 11.4) Pub Date : 2025-04-15 Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Tore K Kvien, Burkhard F Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A Provan, Anja Strangfeld, Trokovic Nina, Jakub
ObjectiveTo assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.MethodsRA patients from 15 registries in the JAK‐pot collaboration were included. MACE incidence was analysed using two approaches: a